Bio-Rad Laboratories Inc. Adds to Growth With Research Spending

Bio-Rad Laboratories Inc. Adds to Growth With Research Spending

A Member of Pat McKeough’s Inner Circle recently asked for his advice on a global developer, manufacturer, and distributor of specialized technological instruments, software, and consumables for the life science research and clinical diagnostics markets.

Pat likes the firm’s attractive combination of defensive cash generation and high-upside exposure to advanced molecular biology. Activist investor interest could also be a plus for a higher share price. However, Pat notes prolonged softness across academic and early-stage biopharma spending has held back earnings.

Bio-Rad Laboratories Inc. (Symbol BIO on New York; www.bio-rad.com) is a multinational manufacturer and worldwide distributor of its own life science research and clinical diagnostics products.

Those products and systems are used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad’s customers operate in life sciences research, healthcare, analytical chemistry and other markets.

Bio-Rad has direct operations in over 36 countries outside the U.S. The company generates 46% of its revenue from the U.S. and 56% from its international locations, with Europe being the largest international region.

Bio-Rad operates two segments: Life Science (40% or revenue) and Clinical Diagnostics (60%).

Life Science develops, makes, and markets instruments, systems, reagents, and consumables. These products help separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids. They assist in research and development, quality control processes, food safety testing, and science education applications.

The segment offers thousands of life science products distributed globally. It serves the research market, where its products support scientific discovery, from early research through clinical and applied use.

linical Diagnostics designs, makes, markets, and supports diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. Its products address the in-vitro diagnostics (IVD) market.

The segment supplies several thousand products, supporting more than 300 clinical tests within the IVD market. The tests identify and measure substances in patient tissue, blood, or urine samples.
[ofie_ad]

Bio-Rad’s revenue up, profits down in the latest quarter

In the three months ended September 30, 2026, Bio-Rad’s revenue rose 0.5%, to $656.4 million from $653.0 million a year earlier. Revenue rose due to higher sales in the Clinical Diagnostics segment, which offset declines in the Life Science segment.

Life Science segment revenue fell 2.8%, to $254.6 million from $261.9 million. The decline was mostly driven by lower process-chromatography sales and ongoing challenges in the academic research market, partially offset by increased Droplet Digital PCR sales. Clinical Diagnostics revenue was $401.8 million, up 2.7% from $391.2 million., mostly driven by growth in quality systems and diabetes products.

Excluding one-time items, earnings were $71.5 million, or $2.65 a share, in the latest quarter. That was up 17.6% from $60.8 million, or $2.26 a share. The increase reflects the higher revenue, profit margin expansion from transformation initiatives, and a lower effective tax rate driven by the geographical mix of earnings.

Bio-Rad’s shares are down significantly from their high of $833 in September 2021. The decline in share price since then is due to several factors. First, COVID-19-related revenue has dried up in the years after the pandemic. Second, academic research funding has declined due to policy shifts by the U.S. government. Third, demand in key markets, such as China, has weakened.

This situation has attracted the interest of Elliott Investment Management, an activist hedge fund with about $80 billion in assets. Elliott specializes in buying large shareholdings in underperforming companies. It then pushes management to aggressively overhaul their businesses with a view to driving up their stock prices.

Elliott has reportedly now built a large stake in Bio-Rad. That could sharpen investor focus on Bio-Rad’s structure. That includes highlighting its major link to Sartorius AG, a German company that serves makers of biologic drugs.

Elliott is also a large investor in Sartorius, while Bio-Rad’s own stake in Sartorius is valued at about $5 billion. That holding could possibly become a key part of Elliott’s plan, as it assesses whether Bio-Rad has room to unlock value with its Sartorius interest,

Meanwhile, the outlook for Bio-Rad is mixed. Reduced academic research spending should continue to weigh on the company’s financial results. However, biotech spending appears to be stabilizing following the post-pandemic correction. This, along with the rollout of new products such as Bio-Rad’s Droplet Digital PCR platform and acquisitions, should support the company’s revenue in the years to come.

Meanwhile, exactly how Bio-Rad will respond to Elliott’s pressure is uncertain. Still, the activist’s interest does draw attention to Bio-Rad’s growth prospects.

Recommendation in Pat’s Inner Circle: Bio-Rad Laboratories Inc. is okay to hold for aggressive investors.

A professional investment analyst for more than 30 years, Pat has developed a stock-selection technique that has proven reliable in both bull and bear markets. His proprietary ValuVesting System™ focuses on stocks that provide exceptional quality at relatively low prices. Many savvy investors and industry leaders consider it the most powerful stock-picking method ever created.